Phaseline

Targets › KISS1R

KISS1R (KiSS-1 receptor): drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 2, 1 Phase 1; Infectious disease, Metabolic and endocrine; next expected readout May 2028.

Receptor for kisspeptins (kisspeptin-10, kisspeptin-13, kisspeptin-14 and metastin/kisspeptin-54). The hypothalamic KISS1/KISS1R signaling system plays a central role in the regulation of the hypothalamic-pituitary-gonadal reproductive axis by modulating the secretion of gonadotropin-releasing hormone (GnRH) from GnRH neurons. (UniProt, Q969F8)

Open in Phaseline: the race on KISS1R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Stephanie B. Seminara, MDKisspeptin 112-121 (Metastin 45-54)
GPR54 (KISS1R) agonist
KISS1RPhase 2Hypogonadotropic Hypogonadism; Hypothalamic Amenorrhea; Reproductive DisorderMay 2028

Conditions

Hypogonadotropic Hypogonadism (1) Hypothalamic Amenorrhea (1) Reproductive Disorder (1)

Modalities

small molecule (1)

Companies

Stephanie B. Seminara, MD (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.